Trial Profile
Pilot Trial to Evaluate Change in Positron Emission Tomography Scanning (PET) as a Surrogate for Zoledronate (Zometa) Efficacy in Patients With Metastatic Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 02 Jun 2015 Primary endpoint has not been met, according to results presented in ASCO abstract.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).
- 02 Jun 2015 Status changed from active, no longer recruiting to completed, as reported in ASCO abstract.